Posted by Michael Wonder on 21 Apr 2021
GW Pharmaceuticals receives European Commission approval for Epidyolex (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex
20 April 2021 - Tuberous sclerosis complex represents a third indication for GW’s cannabidiol in Europe.
GW Pharmaceuticals today announces that the European Commission has approved the Type II variation application for Epidyolex (cannabidiol) as an adjunctive treatment of seizures associated with tuberous sclerosis complex, for patients two years of age and older.
